Welcome to our dedicated page for Incannex Healthcare news (Ticker: IXHL), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare stock.
Incannex Healthcare Inc. reports company developments tied to its clinical-stage combination therapy pipeline, Nasdaq listing status and capital actions. Recurring updates describe IHL-42X, its oral fixed-dose combination program for obstructive sleep apnea, including clinical development strategy, sleep-medicine research partnerships and FDA Fast Track Designation.
News also covers PSX-001, the company’s oral synthetic botanical research compound formulation for generalized anxiety disorder, along with balance-sheet commentary, share repurchase activity, reverse stock split disclosures and Nasdaq minimum bid price compliance. The company’s communications generally center on clinical progress, regulatory context, financing capacity and public-company capital structure.
Incannex Healthcare Limited (Nasdaq: IXHL) plans to acquire APIRx Pharmaceutical USA for US$93.3 million in an all-scrip transaction. This acquisition will enhance Incannex's standing as a leader in cannabinoid and psychedelic pharmaceuticals. APIRx has 22 active clinical and pre-clinical projects targeting various conditions including pain, dementia, and addiction disorders. The transaction is subject to shareholder approval under ASX listing Rule 7.1, and is expected to reinforce Incannex's intellectual property with 19 granted and 23 pending patents.
Incannex Healthcare Limited (Nasdaq: IXHL) has reported promising preliminary results from its phase 2 clinical trial of IHL-42X, a cannabinoid treatment for obstructive sleep apnea (OSA). Key findings include a 44.4% average reduction in the apnoea hypopnoea index (AHI) across all doses, with 60% of participants achieving a reduction greater than 50% and 20% exceeding 80%. IHL-42X was well tolerated, paving the way for a pre-IND meeting with the FDA on May 11, 2022, and plans for pivotal trials following IND submission. The trial signifies a critical step towards addressing unmet medical needs in OSA treatment.
Incannex Healthcare Limited (Nasdaq: IXHL) has signed a global license agreement with Monash University to develop a novel treatment combining Virtual Reality (VR) and psychedelics aimed at anxiety disorders. This initiative marks the start of a new clinical psychedelic therapy program. The agreement involves three license fees totaling A$800,000, which Incannex will pay at various stages, along with a 7.5% royalty on net sales post-commercialization. Funded by Incannex, the project will be led by esteemed Monash researchers to explore treatment effectiveness and safety.
Incannex Healthcare Limited (Nasdaq: IXHL) has commenced trading its American Depositary Shares (ADS) on the Nasdaq Global Market. Each IXHL ADS represents 25 ordinary shares of the Company. The listing follows the SEC's declaration of effectiveness for its registration statement, allowing broader access to investors interested in medicinal cannabis and psychedelic therapies. Incannex retains its listing on the ASX and completed the Nasdaq listing without a capital raise. The listing aims to enhance visibility and facilitate U.S. FDA approval for its therapeutic pipeline.